

Disclaimer


- The information contained in this confidential document ("Presentation") has been prepared by Swissray Global Healthcare Holding Limited (the "Company"). It has not been fully verified and is subject to material updating, revision and further amendment.
- While the information contained herein has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as "Information") and liability therefore is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation.
- Neither the issue of this Presentation nor any part of its contents is to be taken as any form of commitment on the part of the Company to proceed with any transaction and the right is reserved to terminate any discussions or negotiations with any prospective investors. In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation which may become apparent.
- This Presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this Presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.
- This Presentation includes certain statements that may be deemed "forward-looking statements". All statements in this discussion, other than statements of historical facts, that address future activities and events or developments that the Company expects, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and that actual results or developments may differ materially from those projected in forward-looking statements.



Swissray Global Healthcare Holding Ltd. (4198) Investor Conference

Gilbert Wai, CEO
December 20, 2018

Company Organizational Structure



Hochdorf, Switzerland



New Jersey, USA




Wisconsin, USA



Taipei, Taiwan

Available Products



Swissray Product

■ DR- *ddRAura* Series

- *ddRAura* OTC (APS)

Full digitalized ceiling-mounted digital X-ray system with automatic position (APS), auto-tracking function and unique single focus stitching function to support all sorts of clinical studies. *ddRAura* OTC (APS) is the most comprehensive and primium system in digital X-ray industry.

- *ddRAura* FMTS

Full digitalized floor-mounted digital X-ray, easy to use system with auto-tracking function to support all sorts of clinical studies.

- *ddRAura* U

Full digitalized automatic C-arm digital X-ray system with small foot print, automatic position (APS) and unique single focus stitching function to support all sorts of clinical studies.

- *ddRAura* S

Full digitalized manual C-arm digital X-ray system with small foot print, easy to use and support all sorts of clinical studies.

- *ddRAura* Drive Kit

Digital upgrade kit to convert analog or CR X-ray system to a fully digitalized machine.

Swissray Product

■ Magnetic Resonance Imaging System--*SRPulse 710*

- Wide referral base with 71cm bore
- Zero Boil-off
- High image quality
- Maximal throughput
- Real Productive Workhorse

Swissray Product

■ Dual-energy X-ray absorptiometry- Norland DXA Series

- Elite

Premium whole body DXA system dedicated for obesity, sport and military market.

- XR-800

Whole body DXA system for all sorts of bone density and body composition clinical measurements and researches.

- XR-600

Body part DXA system for all sorts of bone density and body composition clinical measurements and researches.

Business Update

■ X-ray

- *ddRAura* received FDA & CE approval. The system is promoted as a upgrade option for the end user of *ddRFormula* & *ddRElement*. As a result, the margin of equipment sales in US has shown improvement compare to last year's outcome.
- The US Service team setup a new company and took over the contractual works in related to service & support, after-sales service and etc. The organization restructure improved profit and controlled expenses.

■ Norland- Bone Densitometry

- Elite successfully entered in the sports market in the United States. Targeted NCAA, NBA & NFL to expand the brand awareness.
- Although XR600 and XR800 are affected by the US-China trade war, new distribution agreements are still increasing in the other Asia countries.

Business Update_ *continued*

■ MRI

- The first system successfully installed at Ackerman Cancer Centre in Florida.
- With the impact of 25% tariff on US import goods, three (3) of the sales contracts were cancelled. This will result in less sales focus in the US & Europe markets, and more in Asia.

■ Ortho-K Lens

- Main goal: target Taiwan & China markets
- Future objective: product registration, manufacture certification and other related preparation
- Established a factory in Taiwan
- Completed training in relate to manufacturing
- Applied ISO13485 in November 2018
- In progress: undergo GMP, conduct clinical trials, apply FDA

Operating Strategy

- First priority: continue to reduce losses and increase cash inflows
- Control costs and overall operating expenses
- Uphold the value of Swissray and Norland brands in the imaging industry
- Increasingly put more effort in the ophthalmology business

Ophthalmic Optics



Orthokeratology (Ortho-k)

- Orthokeratology is a non-surgical, non-permanent vision correction method. An eye doctor based on certain factors to customized patient's ortho-k lens (a.k.a. plastic film), such as patient's eye refraction, corneal shape & size, and etc. Patients generally wear the lenses before bedtime and remove them in the morning, an average of 6-10 hours a day for wearing time. This is a medical treatment that does not require glasses to correct myopia.
- The origin of the word “Orthokeratology” comes from “ortho” (from Greek orthos ‘straight, right’) + “kerato” (from Greek keras, kerat ‘relating to cornea’) + “logy” (from Greek ‘logic’). In Taiwan, we call it orthokeratology, and the lens is refer to plastic film.

Difference between Orthokeratology lenses and contact lenses

■ General Contact Lenses


- The middle portion of the interior arc is steeper and the periphery becomes flatter, which is in line with the curvature of normal cornea.

■ Orthokeratology Lenses

- By applying the design of reverse geometry, the central of the lens is situated flatter than the cornea in order to press on the cornea; connect externally with a steep reverse arc to set the lens and hold the corneal surface that is flattened and move to the periphery; followed by a parallel corneal radius fixed arc to maintain the stability of the lens. By using this unique design, the lens will apply pressure to the surface of the cornea, and force the epithelial cells to re-arrange during sleep. This make the top of the cornea to be flat and increase the incline at the peripheral area further reduce near sight and astigmatism.



Why?



Market Overview of Orthokeratology Lens in Greater China

- It is estimated that the population over the age of 5 with myopia will increase to approximately 51% in 2020 , which comes up to about 700 million of population.
- Over 75 million of elementary & middle school students are myopia.
- Laser surgery and orthokeratology lenses are the two main methods to relieve and treat myopia. As teenagers are still in their developmental stage and laser surgery is not an option, orthokeratology lenses becomes the ideal choice for this group of people to correct their vision.
- Average market price is about RMB 6000
- Potential market size RMB 5 billion


Market Overview of Orthokeratology Lens in Greater China_ *continued*

Myopia rate of students in elementary, middle, high schools in Shanghai:

In year 2016= 37.34%, 69.00% & 85.12%

In year 1990= 16.50%, 39.80% & 68.40%

Growth rate of 20.54%, 29.20% & 16.72%



New Update

- Established Ophthalmic Optical Care Department
- The first set of production equipment has been successfully installed and situated in the Taiwan factory.
- The factory in Taiwan applied ISO13485 in November 2018
- Actions in progress: conduct training, build up consultant team, apply GMP Good Manufacturing Practice Certification
- Plans for the next step: review and study regulation and clinical trials in relate to product registration in Taiwan & China



Thank you for your time.